- Quest Diagnostics press release ( NYSE: DGX ): Q2 Non-GAAP EPS of $2.36 beats by $0.10 .
- Revenue of $2.45B (-3.9% Y/Y) beats by $110M .
- Second quarter base business revenues of $2.10 billion, up 2.9% from 2021
- Full year 2022 reported diluted EPS now expected to be between $8.24 and $8.64; and adjusted diluted EPS expected to be between $9.55 and $9.95 from prior adj. EPS of $9.00-$9.50 vs. $9.30 consensus
- Revenue of $9.5B-$9.75B from prior revenue of $9.2B-$9.5B vs. $9.4B consensus.
For further details see:
Quest Diagnostics Non-GAAP EPS of $2.36 beats by $0.10, revenue of $2.45B beats by $110M, raises FY22 guidance